HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Junnikkala, S. Articles by Meri, S. Search for Related Content PubMed PubMed Citation Articles by Junnikkala, S. Articles by Meri, S.

Exceptional Resistance of Human H2 Glioblastoma Cells to Complement-Mediated Killing by Expression and Utilization of Factor H and Factor H-Like Protein 1¹

S. Junnikkala^*, T. S. Jokiranta^*, M. A. Friese, H. Jarva^*, P. F. Zipfel and S. Meri^2,*

^* Department of Bacteriology and Immunology, Haatman Institute, University of Helsinki, Helsinki, Finland; and Research Group for Biomolecular Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

Of over 20 nucleated cell lines we have examined to date, human H2 glioblastoma cells have turned out to be the most resistant to complement-mediated cytolysis in vitro. H2 cells expressed strongly the membrane attack complex inhibitor protectin (CD59), moderately CD46 (membrane cofactor protein) and CD55 (decay-accelerating factor), but no CD35 (complement receptor 1). When treated with a polyclonal anti-H2 Ab, anti-CD59 mAb, and normal human serum, only 5% of H2 cells became killed. Under the same conditions, 70% of endothelial-like EA.hy 926 cells and 40% of U251 control glioma cells were killed. A combined neutralization of CD46, CD55, and CD59 increased H2 lysis only minimally, demonstrating that these complement regulators are not enough to account for the resistance of H2 cells. After treatment with Abs and serum, less C5b-9 was deposited on H2 than on U251 and EA.hy 926 cell lines. A reason for the exceptional resistance of H2 cells was revealed when RT-PCR and protein biochemical methods showed that the H2 cells, unlike the other cell lines tested, actively produced the soluble complement inhibitors factor H and factor H-like protein 1. H2 cells were also capable of binding human factor H from the fluid phase to their cell surface and promoted the cleavage of C3b to its inactive form iC3b more efficiently than U251 and EA.hy 926 cells. In accordance, anti-factor H mAbs enhanced killing of H2 glioblastoma cells. Taken together, our results show that production and binding of factor H and factor H-like protein 1 is a novel mechanism that these malignant cells utilize to escape complement-mediated killing.

This article has been cited by other articles:

				M. R. Griffiths, J. W. Neal, M. Fontaine, T. Das, and P. Gasque Complement Factor H, a Marker of Self Protects against Experimental Autoimmune Encephalomyelitis J. Immunol., April 1, 2009; 182(7): 4368 - 4377. [Abstract] [Full Text] [PDF]

				D. Ajona, Y.-F. Hsu, L. Corrales, L. M. Montuenga, and R. Pio Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth J. Immunol., May 1, 2007; 178(9): 5991 - 5998. [Abstract] [Full Text] [PDF]

				V. P. Ferreira, A. P. Herbert, H. G. Hocking, P. N. Barlow, and M. K. Pangburn Critical Role of the C-Terminal Domains of Factor H in Regulating Complement Activation at Cell Surfaces J. Immunol., November 1, 2006; 177(9): 6308 - 6316. [Abstract] [Full Text] [PDF]

				T. S. Jokiranta, Z.-Z. Cheng, H. Seeberger, M. Jozsi, S. Heinen, M. Noris, G. Remuzzi, R. Ormsby, D. L. Gordon, S. Meri, et al. Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site Am. J. Pathol., October 1, 2005; 167(4): 1173 - 1181. [Abstract] [Full Text] [PDF]

				Z.-Z. Cheng, M. J. Corey, M. Parepalo, S. Majno, J. Hellwage, P. F. Zipfel, R. J. Kinders, M. Raitanen, S. Meri, and T. S. Jokiranta Complement Factor H as a Marker for Detection of Bladder Cancer Clin. Chem., May 1, 2005; 51(5): 856 - 863. [Abstract] [Full Text] [PDF]

				D. Ajona, Z. Castano, M. Garayoa, E. Zudaire, M. J. Pajares, A. Martinez, F. Cuttitta, L. M. Montuenga, and R. Pio Expression of Complement Factor H by Lung Cancer Cells: Effects on the Activation of the Alternative Pathway of Complement Cancer Res., September 1, 2004; 64(17): 6310 - 6318. [Abstract] [Full Text] [PDF]

				C. A. Koch, Z. I. Khalpey, and J. L. Platt Accommodation: Preventing Injury in Transplantation and Disease J. Immunol., May 1, 2004; 172(9): 5143 - 5148. [Abstract] [Full Text] [PDF]

				T. Areschoug, M. Stalhammar-Carlemalm, I. Karlsson, and G. Lindahl Streptococcal beta Protein Has Separate Binding Sites for Human Factor H and IgA-Fc J. Biol. Chem., April 5, 2002; 277(15): 12642 - 12648. [Abstract] [Full Text] [PDF]

				M. T. Holmberg, A. M. Blom, and S. Meri Regulation of Complement Classical Pathway by Association of C4b-Binding Protein to the Surfaces of SK-OV-3 and Caov-3 Ovarian Adenocarcinoma Cells J. Immunol., July 15, 2001; 167(2): 935 - 939. [Abstract] [Full Text] [PDF]

				J. J. Alexander, B. K. Hack, P. N. Cunningham, and R. J. Quigg A Protein with Characteristics of Factor H Is Present on Rodent Platelets and Functions as the Immune Adherence Receptor J. Biol. Chem., August 17, 2001; 276(34): 32129 - 32135. [Abstract] [Full Text] [PDF]